Limited use of compulsory licensing of pharmaceuticals to protect public health. Reed Beall and Randall Kuhn of the University of Denver, USA describe in this week's PLoS Medicine their findings ...

However, several developing countries do not have the capacities to produce pharmaceutical products domestically, which limits the utility of compulsory licensing. To address this issue, the WTO ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Compulsory licensing became popular in global health in the early 2000s to ensure low-priced HIV medicines could ... This situation further strengthens the market position of pharmaceutical ...

On July 25, Rep. Lloyd Doggett (D-Texas) introduced H.R. 6505, The Medicare Negotiation and Competitive Licensing Act. The bill currently has 82 cosponsors, all Democrats. A pre… ...

Limited use of compulsory licensing of pharmaceuticals to protect public health. Reed Beall and Randall Kuhn of the University of Denver, USA describe in this week's PLoS Medicine their findings from ...

“Confrontational approaches such as compulsory licensing are time consuming, risky and an ultimately unsustainable way of addressing global health challenges. Voluntary licensing, by contrast ...

AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir.

Pharma industry bodies have slammed a proposal by the European Commission to set up a compulsory licensing (CL) framework for medicines in emergency situations, claiming there is no need for the move.

According to GlobalData, Both Johnson & Johnson and Pfizer criticized the changes by referencing the positive role of patents in incentivizing their vaccine production during the COVID-19 pandemic.